Calculate mRNA Oncology Vaccine Deal Values Instantly
Get accurate licensing valuations based on latest Moderna/Merck market data and 30% oncology premium.
Calculate NowMarket-Leading Accuracy
Built on real mRNA oncology deals including Moderna/Merck partnerships. Our algorithm incorporates the 30% valuation premium driving today's market.
Instant Deal Scenarios
Generate Phase 2 upfront payments and total deal structures in seconds. Compare multiple scenarios to optimize your negotiation strategy.
Current Market Data
Access the latest benchmarking data with typical Phase 2 upfronts of $60M-$250M and total deal values reaching $2.5B for leading programs.
$2.5B
Peak Deal Values
50+
mRNA Deals Analyzed
30%
Oncology Premium
$250M
Max Phase 2 Upfront
How It Works
Input Program Details
Enter your mRNA oncology vaccine's stage, indication, and key clinical parameters
Apply Market Benchmarks
Our algorithm compares against 50+ mRNA deals with automatic oncology premium adjustment
Generate Deal Terms
Receive detailed upfront, milestone, and royalty structures with comparable deal references
Frequently Asked Questions
How does the 30% oncology premium affect valuations?
What Phase 2 upfront should I expect for my program?
How do Moderna/Merck deals influence the market?
Can I model different partnership scenarios?
Ready to Calculate Your Deal Terms?
Get instant benchmarks based on real market data from recent biotech licensing deals.
Start Calculating